Staphylococcus Aureus

2
Pipeline Programs
5
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Bristol Myers Squibb
1 program
1
Aurexis®Phase 21 trial
Active Trials
NCT00198289Completed30Est. Jun 2006
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
1
nasal microbiota transplantPhase 11 trial
Active Trials
NCT05695196Active Not RecruitingEst. Dec 2026
M&
Merck & Co.RAHWAY, NJ
1 program
Antimicrobial Drug Use and Resistant Staphylococcus AureusN/A1 trial
Active Trials
NCT01075451CompletedEst. May 2013
Pfizer
PfizerNEW YORK, NY
1 program
Staphylococcus Aureus Surgical Site Infection Multinational Epidemiology in EuropeN/A1 trial
Active Trials
NCT03353532Completed178,902Est. Jan 2021
Astellas
AstellasChina - Shenyang
1 program
The Causes and Interpretation of Low-level Resistance in Staphylococcus AureusN/A1 trial
Active Trials
NCT01127516Completed45Est. May 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Bristol Myers SquibbAurexis®
Allergy Therapeuticsnasal microbiota transplant
PfizerStaphylococcus Aureus Surgical Site Infection Multinational Epidemiology in Europe
AstellasThe Causes and Interpretation of Low-level Resistance in Staphylococcus Aureus
Merck & Co.Antimicrobial Drug Use and Resistant Staphylococcus Aureus

Clinical Trials (5)

Total enrollment: 178,977 patients across 5 trials

NCT00198289Bristol Myers SquibbAurexis®

Aurexis® in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs

Start: Apr 2005Est. completion: Jun 200630 patients
Phase 2Completed
NCT05695196Allergy Therapeuticsnasal microbiota transplant

Feasibility and Safety Study of Parent-to-Child Nasal Microbiota Transplant

Start: Oct 2023Est. completion: Dec 2026
Phase 1Active Not Recruiting
NCT03353532PfizerStaphylococcus Aureus Surgical Site Infection Multinational Epidemiology in Europe

Staphylococcus Aureus Surgical Site Infection Multinational Epidemiology in Europe

Start: Aug 2017Est. completion: Jan 2021178,902 patients
N/ACompleted
NCT01127516AstellasThe Causes and Interpretation of Low-level Resistance in Staphylococcus Aureus

The Causes and Interpretation of Low-level Resistance in Staphylococcus Aureus

Start: Apr 2010Est. completion: May 201345 patients
N/ACompleted
NCT01075451Merck & Co.Antimicrobial Drug Use and Resistant Staphylococcus Aureus

Antimicrobial Drug Use and Resistant Staphylococcus Aureus

Start: Jan 2010Est. completion: May 2013
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 companies competing in this space